Tasly Pharmaceutical Reports 11.05 Billion Yuan Net Profit for 2025, Marking 15.68% Year-on-Year Growth

Stock News02-06 20:46

CHINARES PHARMA (03320) has released the unaudited preliminary financial data for Tasly Pharmaceutical Group Co.,Ltd. for the year ended December 31, 2025. Tasly Pharmaceutical achieved total operating revenue of 8.236 billion yuan, representing a decrease of 3.08% compared to the previous year. The net profit attributable to shareholders of the listed company was 1.105 billion yuan, indicating a year-on-year increase of 15.68%. In terms of the changes, the primary reason for the decline in operating revenue was a 14.24% year-on-year reduction in pharmaceutical commercial revenue, primarily from its chain pharmacy business, which was affected by industry-wide policies such as "outpatient统筹" (outpatient coordinated billing).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114832908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114832908","market":"sh","top_or_hot":-1,"title":"Tasly Pharmaceutical Reports 11.05 Billion Yuan Net Profit for 2025, Marking 15.68% Year-on-Year Growth","media":"Stock News","content":"<p>CHINARES PHARMA (03320) has released the unaudited preliminary financial data for Tasly Pharmaceutical Group Co.,Ltd. for the year ended December 31, 2025. Tasly Pharmaceutical achieved total operating revenue of 8.236 billion yuan, representing a decrease of 3.08% compared to the previous year. The net profit attributable to shareholders of the listed company was 1.105 billion yuan, indicating a year-on-year increase of 15.68%. In terms of the changes, the primary reason for the decline in operating revenue was a 14.24% year-on-year reduction in pharmaceutical commercial revenue, primarily from its chain pharmacy business, which was affected by industry-wide policies such as \"outpatient统筹\" (outpatient coordinated billing).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly Pharmaceutical Reports 11.05 Billion Yuan Net Profit for 2025, Marking 15.68% Year-on-Year Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly Pharmaceutical Reports 11.05 Billion Yuan Net Profit for 2025, Marking 15.68% Year-on-Year Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-06 20:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CHINARES PHARMA (03320) has released the unaudited preliminary financial data for Tasly Pharmaceutical Group Co.,Ltd. for the year ended December 31, 2025. Tasly Pharmaceutical achieved total operating revenue of 8.236 billion yuan, representing a decrease of 3.08% compared to the previous year. The net profit attributable to shareholders of the listed company was 1.105 billion yuan, indicating a year-on-year increase of 15.68%. In terms of the changes, the primary reason for the decline in operating revenue was a 14.24% year-on-year reduction in pharmaceutical commercial revenue, primarily from its chain pharmacy business, which was affected by industry-wide policies such as \"outpatient统筹\" (outpatient coordinated billing).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600535","symbol_name":"天士力","start_time":0,"source_url":"","article_id":"1114832908","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114832908","pubTimestamp":1770381977,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) has released the unaudited preliminary financial data for Tasly Pharmaceutical Group Co.,Ltd. for the year ended December 31, 2025. Tasly Pharmaceutical achieved total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600535":"天士力","BK0239":"医药制造","BK0183":"MSCI概念","BK0028":"国家队","BK1191":"制药","BK0188":"融资融券","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1570":"华润系","BK0012":"证金概念","BK0196":"行业龙头","BK1574":"生物医药B类股","03320":"华润医药"},"translate_title":"天士力药业2025年净利110.5亿元同比增长15.68%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600535":1,"03320":1,"09939":1},"content_text":"CHINARES PHARMA (03320) has released the unaudited preliminary financial data for Tasly Pharmaceutical Group Co.,Ltd. for the year ended December 31, 2025. Tasly Pharmaceutical achieved total operating revenue of 8.236 billion yuan, representing a decrease of 3.08% compared to the previous year. The net profit attributable to shareholders of the listed company was 1.105 billion yuan, indicating a year-on-year increase of 15.68%. In terms of the changes, the primary reason for the decline in operating revenue was a 14.24% year-on-year reduction in pharmaceutical commercial revenue, primarily from its chain pharmacy business, which was affected by industry-wide policies such as \"outpatient统筹\" (outpatient coordinated billing).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114832908","isCrawlerRequest":true}